Press Releases Keyword Search Year: 20202019201820172016201520142013 Nov 3, 2016 Summary ToggleAgios Reports Third Quarter 2016 Financial Results and Reviews Recent Progress in IDH and PKR Development Programs Nov 1, 2016 Summary ToggleAgios to Present at the 25th Annual Credit Suisse Healthcare Conference Tuesday, November 8, 2016 Oct 27, 2016 Summary ToggleAgios to Webcast Conference Call of Third Quarter 2016 Financial Results on November 3, 2016 Oct 12, 2016 Summary ToggleCelgene and Agios Announce Collaborations with Abbott for Diagnostic Identification of IDH Mutations in AML Sep 20, 2016 Summary ToggleAgios Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares Sep 14, 2016 Summary ToggleAgios Announces Pricing of $150 Million Public Offering of Common Stock Sep 13, 2016 Summary ToggleAgios Announces Proposed Offering of Common Stock Sep 6, 2016 Summary ToggleAgios to Present at Morgan Stanley Global Healthcare Conference Tuesday, September 13, 2016 Aug 16, 2016 Summary ToggleAgios Appoints Andrew Hirsch as Chief Financial Officer Aug 5, 2016 Summary ToggleAgios to Present at Canaccord Genuity 36th Annual Growth Conference Wednesday, August 10, 2016 Aug 4, 2016 Summary ToggleAgios Reports Second Quarter 2016 Financial Results Jul 28, 2016 Summary ToggleAgios to Webcast Conference Call of Second Quarter 2016 Financial Results on August 4, 2016 Jun 11, 2016 Summary ToggleAG-348 Achieves Proof-of-Concept in Ongoing Phase 2 DRIVE-PK Study and Demonstrates Rapid and Sustained Hemoglobin Increases in Adults with Pyruvate Kinase Deficiency Jun 9, 2016 Summary ToggleAgios Reports Initial Data from Phase 1 Study of AG-519 in Healthy Volunteers Jun 1, 2016 Summary ToggleAgios to Host Conference Call from the 21st Congress of the European Hematology Association May 19, 2016 Summary ToggleAgios to Present Clinical and Preclinical Data from PKR Activators AG-348 and AG-519 at the 21st Congress of the European Hematology Association May 17, 2016 Summary ToggleAgios Updates 2016 Financial Guidance May 17, 2016 Summary ToggleAgios and Celgene Establish New Collaboration in Metabolic Immuno-Oncology and Amend Certain Rights from 2010 Agreement May 5, 2016 Summary ToggleAgios Reports First Quarter 2016 Financial Results May 2, 2016 Summary ToggleAgios to Webcast Conference Call of First Quarter 2016 Financial Results on May 5, 2016 Mar 30, 2016 Summary ToggleAgios Announces Initiation of Phase 1/2 Frontline Combination Study of AG-221 or AG-120 with VIDAZA® (azacitidine for injection) in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients Not Eligible for Intensive Chemotherapy Mar 1, 2016 Summary ToggleAgios to Present at the Cowen and Company 36th Annual Health Care Conference on Tuesday, March 8 Feb 18, 2016 Summary ToggleAgios Reports Fourth Quarter and Full Year 2015 Financial Results and Highlights Key 2016 Milestones Feb 11, 2016 Summary ToggleAgios to Webcast Conference Call of Fourth Quarter and Full Year 2015 Financial Results on February 18, 2016 Feb 8, 2016 Summary ToggleAgios Appoints Steve Hoerter as Chief Commercial Officer Feb 3, 2016 Summary ToggleAgios to Present at the Leerink Partners 5th Annual Global Healthcare Conference on Wednesday, February 10 Jan 11, 2016 Summary ToggleAgios Outlines Key 2016 Goals and Priorities Jan 4, 2016 Summary ToggleAgios to Present at the 34th Annual J.P. Morgan Healthcare Conference on Monday, January 11 Dec 18, 2015 Summary ToggleAgios Announces Initiation of Phase 1b Frontline Trial of AG-221 or AG-120 in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients Dec 6, 2015 Summary ToggleAgios Announces Data from Ongoing Phase 1/2 Trial of AG-221 Showing Durable Responses in Patients with Advanced Hematologic Malignancies Dec 5, 2015 Summary ToggleAgios Announces Data from Ongoing Phase 1 Trial of AG-120 Showing Durable Responses in Patients with Advanced Hematologic Malignancies Nov 8, 2015 Summary ToggleAgios Announces Data from Dose-Escalation Phase 1 Study of AG-120 in Patients with IDH1 Mutant Positive Advanced Solid Tumors Nov 5, 2015 Summary ToggleAgios to Present New Data From Lead Programs at the 2015 ASH Annual Meeting Nov 5, 2015 Summary ToggleAgios Reports Third Quarter 2015 Financial Results Nov 3, 2015 Summary ToggleAgios to Present at Credit Suisse 24th Annual Healthcare Conference on Tuesday, November 10 Oct 29, 2015 Summary ToggleAgios to Webcast Conference Call of Third Quarter 2015 Financial Results on November 5, 2015 Oct 26, 2015 Summary ToggleAgios to Present Clinical Data from Ongoing AG-120 Phase 1 Trial in Advanced Solid Tumors at AACR-NCI-EORTC Oct 16, 2015 Summary ToggleAgios Outlines Key Clinical Development & Research Strategies Oct 8, 2015 Summary ToggleAgios to Webcast R&D Day on October 16, 2015 Sep 23, 2015 Summary ToggleAgios to Present at Leerink Partners Rare Disease Roundtable Aug 6, 2015 Summary ToggleAgios Reports Second Quarter 2015 Financial Results and Provides Updates on Clinical Development Progress Aug 5, 2015 Summary ToggleAgios to Present at Canaccord Genuity 35th Annual Growth Conference Wednesday, August 12, 2015 Jul 30, 2015 Summary ToggleAgios to Webcast Conference Call of Second Quarter 2015 Financial Results on August 6, 2015 Jun 24, 2015 Summary ToggleAgios Announces First Patient Dosed with AG-881 in Phase 1 Study in Patients with Advanced Solid Tumors with an IDH Mutation Jun 23, 2015 Summary ToggleAgios Appoints Maykin Ho, Ph.D., to its Board of Directors Pagination First page First Previous page Previous … Page 3 Current page 4 Page 5 Page 6 … Next page Next Last page Last